mb glp-1 reviews Glucagon-like peptide 1 in health and disease Cardiovascular Effects and Tolerability of

In the Phase 3 TRIUMPH-4 trial, 33% of participants on the 12 mg dose reported diarrhea compared to 13.4% on placebo (Wang et al., Syst Rev Meta-Analysis, 2025)

This means it may affect more than one part of the bodys metabolic system, including appetite control, insulin response, blood sugar balance, and fat metabolism

Cardiometabolic Markers Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism

Converting it to an injectable solution requires bacteriostatic water and careful technique